Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5338559 | 0.90 | RAB9A (0.49) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL5225328 | 0.83 | POLB (0.50) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL5223942 | 0.81 | RAB9A (0.48) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6634717 | 0.81 | SMN1; SMN2 (0.44) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6635132 | 0.80 | SMN1; SMN2 (0.43) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6691951 | 0.80 | RAB9A (0.42) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6635325 | 0.79 | MAPT (0.45) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6633203 | 0.79 | RAB9A (0.40) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL5221849 | 0.78 | POLB (0.48) | RAB9APOLBMAPTNPC1ALDH1A1 | |
| SCHEMBL6685625 | 0.75 | DRD2 (0.41) | MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | RAB9A 608/4885POLB 4233/4885MAPT 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.